Lutetium-177 labeled peptides: The European institute of oncology experience

Current Radiopharmaceuticals

Volumn 9, Issue 1, 2016, Pages 19-32

  Carollo, Angela ^a   Papi, Stefano ^a   Chinol, Marco ^a  

^a EUROPEAN INSTITUTE OF ONCOLOGY   (Italy)

Author keywords

177Lu DOTATATE; DOTA peptide; GEP NETs; Lutetium 177; PRRT; Quality control; emitter

Indexed keywords

LUTETIUM 177; PEPTIDE; PYROGEN; RADIOISOTOPE; SOMATOSTATIN DERIVATIVE; LUTETIUM; RADIOPHARMACEUTICAL AGENT; RECEPTOR; SOMATOSTATIN; SOMATOSTATIN RECEPTOR;

ARTICLE; AUTOMATION; DOSIMETRY; HUMAN; ISOTOPE LABELING; PH; PRIORITY JOURNAL; RADIATION PROTECTION; TEMPERATURE SENSITIVITY; WASTE MANAGEMENT; ANALOGS AND DERIVATIVES; MEDICINAL CHEMISTRY; METABOLISM; NEUROENDOCRINE TUMORS; PROCEDURES; QUALITY OF LIFE;

CHEMISTRY, PHARMACEUTICAL; HUMANS; LUTETIUM; NEUROENDOCRINE TUMORS; PEPTIDES; QUALITY OF LIFE; RADIOISOTOPES; RADIOPHARMACEUTICALS; RECEPTORS, PEPTIDE; RECEPTORS, SOMATOSTATIN; SOMATOSTATIN;

EID: 84949788142     PISSN: 18744710     EISSN: 18744729     Source Type: Journal    
DOI: 10.2174/1874471008666150313111633     Document Type: Article

References (46)

1. Chinol, M.; Paganelli, G. Radionuclide Peptide Cancer Therapy. Informa Healthcare, 2006.
2. Froidevaux, S.; Eberle, A.N. Somatostatin analogs and radiopeptides in cancer therapy. Biopolymers, 2002, 66 (3), 161-183.
3. Bodei, L.; Chinol, M.; Cremonesi, M.; Paganelli, G. Facts and myths about radiopeptide therapy: Scylla, Charybdis and Sibyl. Eur. J. Nucl. Med. Mol. Imaging, 2002, 29 (8), 1099-1100.
4. Paganelli, G.; Bodei, L.; Handkiewicz Junak, D.; Rocca, P.; Papi, S.; Lopera Sierra, M.; Gatti, M.; Chinol, M.; Bartolomei, M.; Fiorenza, M.; Grana, C. 90Y-DOTA-D-Phe1-Try3-octreotide in therapy of neuroendocrine malignancies. Biopolymers, 2002, 66 (6), 393-8.
5. Otte, A.; Jermann, E.; Behe, M.; Goetze, M.; Bucher, H.C.; Roser, H.W.; Heppeler, A.; Mueller-Brand, J.; Maecke, H.R. DOTATOC: a powerful new tool for receptor-mediated radionuclide therapy. Eur. J. Nucl. Med., 1997, 24(7), 792-795.
6. de Jong, M.; Krenning, E. New Advances in Peptide Receptor Radionuclide Therapy. J. Nucl. Med., 2002, 43, 617-620.
7. Bergsma, H.; van Vliet, E.I.; Teunissen, J.J.M.; Kam, B.L.R.; de Herder, W.W.; Peeters, R.P.; Krenning, E.P.; Kwekkeboom, D.J. Peptide receptor radionuclide therapy (PRRT) for GEP-NETs. Best Pract. Res. Clin. Gastroenterol., 2012, 26, 867-881.
8. Wessels, B.W.; Meares, C.F. Physical and Chemical Properties of Radionuclide Therapy. Semin. Radiat. Oncol., 2000, 110(2), 115-122.
9. Kwekkeboom, D.J.; de Herder, W.W.; Krenning, E.P. Somatostatin Receptor-Targeted Radionuclide Therapy in Patients with Gastroenteropancreatic Neuroendocrine Tumors. Endocrinol. Metab. Clin. N. Am., 2011, 40, 173-185.
10. Gulenchyn, K.Y.; Yaoy, X.; Asa, S.L.; Singh, S.; Law, C. Radionuclide Therapy in Neuroendocrine Tumours: A Systematic Review. Clin. Oncol., 2012, 24, 294-308.
11. Krenning, E.P.; Kwekkeboom, D.J.; Bakker, W.H.; Breeman, W.A.; Kooij, P.P.; Oei, H.Y.; van Hagen, M.; Postema, P.T.; de Jong, M.; Reubi, J.C.; Visser, T.J.; Reijs, A.E.M.; Holland, L.J.; Koper, J.W.; Lamberts, S.W.J. Somatostatin receptor scintigraphy with [111In-DTPA-D-Phe1]-and [123I-Tyr3]-octreotide: the Rotterdam experience with more than 1000 patients. Eur. J. Nucl. Med., 1993, 20(8), 716-731.
12. Nicolas, G.; Giovacchini, G.; Müller-Brand, J.; Forrer, F. Targeted Radiotherapy with Radiolabeled Somatostatin Analogs. Endocrinol. Metab. Clin. N. Am., 2011, 40, 187-204.
13. Saha, G.B. Fundamentals of Nuclear Pharmacy. Sixth Ed., 2010, Springer.
14. Pawlak, D.; Parus, J.L.; Sasinowska, I.; Mikolajczak, R. Determination of elemental and radionuclidic impurities in 177Lu used for labeling of radiopharmaceuticals. Journal of Radioanalytical and Nuclear Chemistry, 2004, 261(2), 469-472.
15. Asti, M.; Tegoni, M.; Farioli, D.; Iori, M.; Guidotti, C.; Cutler, C.S.; Mayer, P.; Versari, A.; Salvo, D. Influence of cations on the complexation yield of DOTATATE with yttrium and lutetium: a perspective study for enhancing the 90Y and 177Lu labeling conditions. Nuclear Medicine and Biology, 2012, 39, 509-517.
16. de Blois, E.; Chan, H.S.; de Zanger, R.; Konijnenberg, M.; Breeman, W.A.P. Application of single-vial ready-for-use formulation of 111In-or 177Lu-labeled somatostatin analogs. Appl. Radiat. Isot., 2014, 85, 28-33.
17. Chang, C.A.; Liu, Y.L.; Chen, C.Y.; Chou, X.M. Ligand Preorganization in Metal Ion Complexation: Molecular Mechanics/ Dynamics, Kinetics, and Laser-Excited Luminescence Studies of Trivalent Lanthanide Complex Formation with Macrocyclic Ligands TETA and DOTA. Inorg. Chem., 2001, 40, 3448-3455.
18. Woods, M.; Kovacs, Z.; Kiraly, R.; Brucher, E.; Zhang, S.; Sherry, A.D. Solution Dynamics and Stability of Lanthanide(III) (S)-2-(p-Nitrobenzyl)DOTA Complexes. Inorg. Chem., 2004, 43, 2845-2851.
19. Mayer, F.; Platas-Iglesias, C.; Helm, L.; Peters, J.A.; Djanashvili, K. 17O NMR and Density Functional Theory Study of the Dynamics of the Carboxylate Groups in DOTA Complexes of Lanthanides in Aqueous Solution. Inorg. Chem., 2012, 51, 170-178.
20. Chaves, S.; Delgado, R.; Da Silva, J.J. The stability of the metal complexes of cyclic tetra-aza tetra-acetic acids. Talanta, 1992, 39(3), 249-254.
21. Clarke, E.T.; Martell, A.E. Stabilities of the alkaline earth and divalent transition metal complexes of the tetraazamacrocyclic tetraacetic acid ligands. Inorg. Ch. Acta, 1991, 1, 37-46.
22. de Goeij, J.J.M.; Bonardi, M.L. How do we define the concepts specific activity, radioactive concentration, carrier, carrier-free and no-carrier-added? Journal of Radioanalytical and Nuclear Chemistry, 2005, 263(1), 13-18.
23. Breeman, W.A.P.; de Jong, M.; Visser, T.J.; Erion, J.L.; Krenning, E.P. Optimising conditions for radiolabeling of DOTA-peptides with 90Y, 111In and 177Lu at high specific activities. Eur. J. Nucl. Med. Mol. Imaging, 2003, 30, 917-920.
24. Duodu, G.O.; Akaho, E.H.K.; Serfor-Armah, Y.; Nyarko, B.J.B.; Afi Achoribo, E. Predicting the yield of 177Lu radionuclide produced by the cyclic irradiation technique. App. Radiat. Isot., 2011, 69, 588-593.
25. Dvorakova, Z.; Henkelmann, R.; Lin, X.; Türler, A.; Gerstenberg, H. Production of 177Lu at the new research reactor FRM-II: Irradiation yield of 176Lu(n,γ)177Lu. App. Radiat. Isot., 2008, 66(2), 147-51.
26. Nir-El, Y. Production of 177Lu by neutron activation of 176Lu. J. Radioanal. Nucl. Chem., 2004, 262(3), 563-567.
27. Lebedev, N.A.; Novgorodov, A.F.; Misiak, R.; Brockmann, J.; Rösch, F. Radiochemical separation of no-carrier-added 177Lu as produced via the 176Yb(n,γ)177Yb®177Lu process. App. Radiat. Isot., 2000, 53(3), 421-425.
28. Horwitz, E.P.; McAlister, D.R.; Bond, A.H.; Barrans, R.E.; Williamson, J.M. A process for the separation of 177Lu from neutron irradiated 176Yb targets. App. Radiat. Isot., 2005, 63(1), 23-36.
29. Manenti, S.; Bonardi, M.L.; Gini, L.; Groppi, F. Physical optimization of production by deuteron irradiation of high specific activity 177gLu suitable for radioimmunotherapy. Nucl. Med. Biol., 2014, 41, 407-409.
30. Chakravarty, R.; Das, T.; Dash, A.; Venkatesh, M. An electroamalgamation approach to isolate no-carrier-added 177Lu from neutron irradiated Yb for biomedical applications. Nucl. Med. Biol., 2010, 37, 811-820.
31. Groppi, F.; Persico, E.; Quartapelle, E.; Gallorini, M.; Bergamaschi, L.; Cantone, M.C. Determination of chemical purity and specific activity of 177g,mLuCl3 by INAA and ET-AAS. J. Radioanal. Nucl. Chem., 2008, 278(3), 595-598.
32. Pillai, M.R.A.; Chakraborty, S.; Das, T.; Venkatesh, M.; Ramamoorthy, N. Production logistics of 177Lu for radionuclide therapy. App. Radiat. Isot., 2003, 59, 109-118.
33. VanSo, L. Specific Radioactivity of Neutron Induced Radioisotopes: Assessment Methods and Application for Medically Useful 177Lu Production as a Case. Molecules, 2011, 16, 818-846.
34. Canella, L.; Bonardi, M.L.; Groppi, F.; Persico, E.; Zona, C.; Menapace, E.; Alfassi, Z.B.; Chinol, M.; Papi, S.; Tosi, G. Accurate determination of half-life and radionuclidic purity of reactor produced 177gLu (177mLu) for metabolic radiotherapy. J. Radioanal. Nucl. Chem., 2008, 276(3), 813-818.
35. Rimpler, A.; Barth, I.; Baum, R.B.; Senftleben, S.; Geworski, L. Beta radiation exposure of staff during and after therapies with 90Ylabeled substances. Radiat. Prot. Dosimetry, 2008, 131 (1), 73-79.
36. Grassi, E.; Sghedoni, R.; Asti, M.; Fioroni, F.; Salvo, D.; Borasi, G. Radiation protection in 90Y-labeled DOTA-D-Phe1-Tyr3-octreotide preparations. Nucl. Med. Commun., 2009, 30, 176-182.
37. Cremonesi, M.; Ferrari, M.; Paganelli, G.; Rossi, A.; Chinol, M.; Bartolomei, M.; Prisco, G.; Tosi, G. Radiation protection in radionuclide therapies with 90Y-conjugates: risks and safety. Eur. J. Nucl. Med. Mol. Imaging, 2006, 33(11), 1321-1327.
38. Papi, S.; Martano, L.; Garaboldi, L.; Rossi, A.; Cremonesi, M.; Grana, C.M.; Paolucci, D.; Sansovini, M.; Paganelli, G.; Chinol, M. Radiolabeling optimization and reduced staff radiation exposure for high-dose 90Y-ibritumomab tiuxetan (HD-Zevalin). Nucl. Med. Biol., 2010, 37, 85-93.
39. Rimpler, A.; Barth, I.; Ferrari, P.; Baechler, S.; Carnicer, A.; Donadille, L.; Fulop, M.; Ginjaume, M.; Mariotti, M.; Sans-Merce, M.; Gualdrini, G.; Krim, S.; Ortega, X.; Ruiz, N.; Vanhavere, F. Extremity exposure in nuclear medicine therapy with 90Y-labeled substances-Results of the ORAMED project. Radiat. Meas., 2011, 46, 1283-1286.
40. Kemerink, G.J.; Vanhavere, F.; Barth, I.; Mottaghy, F.M. Extremity doses of nuclear medicine personnel: a concern. Eur. J. Nucl. Med. Mol. Imaging, 2012, 39, 529-532.
41. Petrik, M.; Knetsch, P.A.; Knopp, R.; Imperato, G.; Ocak, M.; von Guggenberg, E.; Haubner, R.; Silbernagl, R.; Decristoforo, C. Radiolabeling of peptides for PET, SPECT and therapeutic applications using a fully automated disposable cassette system. Nucl. Med. Commun., 2011, 32(10), 887-895.
42. Sirna, V.; Garaboldi, L.; Papi, S.; Martano, L.; Omodeo Salè, E.; Paganelli, G.; Chinol, M. Testing of microbial contamination during the preparation of the radiocompound [90Y]DOTATOC for clinical trials: a process validation study by Media Fill approach. Q. J. Nucl. Med. Mol. Imaging, 2010, 54, 553-559.
43. United States Pharmacopoeia, Section <71>.
44. European Pharmacopoeia, Sterility Test. General Monograph E.P. 2.6.1.
45. Italian Ministry of Health. Norme di Buona Preparazione dei Radiofarmaci per Medicina Nucleare. Gazzetta Ufficiale della Repubblica Italiana, 2005, 168.
46. European Commission, Enterprise and Industry Directorate-General. EU Guidelines to Good Manufacturing Practice Medicinal Products for human and veterinary use. Eudralex Vol. 4, Annex 3: Manufacture of Radiopharmaceuticals.